The Center for Biosimilars® recaps the top stories for the week of November 18, 2019.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 18, 2019.
Number 5: The first patients in a phase 3 trial of PB006, a proposed natalizumab biosimilar, have begun to receive the study drug.
Number 4: Samsung Bioepis announced that the FDA has accepted for review a Biologics License Application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
Number 3: While much attention over the past few weeks has been on the US biosimilars market, Canada has also been making strides in its own biosimilars experience.
Number 2: The US market saw the launch of the third biosimilar pegfilgrastim.
Number 1: The FDA approved Pfizer’s adalimumab biosimilar, referencing Humira.
Finally, last week, our e-newsletter asked whether you think that the 10% list price discount for the first US rituximab biosimilar is deep enough to drive uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.